HIF-1α Stabilizing Compounds for Colitis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for colitis and inflammatory bowel diseases often require surgical intervention and have limitations in effectively managing the condition without significant side effects.
Innovation Solution
Development of compounds that stabilize HIF-1α and HIF-2α, addressing the compromised immune system in colitis and inflammatory bowel diseases, thereby potentially reducing the need for surgery and improving treatment outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for colitis are used, then surgical intervention may be required, but the treatment effectiveness is limited and side effects are significant
Solution Approach 1:
The patent changes the chemical parameter of the treatment by introducing compounds that stabilize HIF-1α and HIF-2α, transitioning from conventional anti-inflammatory and immunosuppressive medications to a novel mechanism of action that addresses the underlying hypoxia and immune dysfunction in colitis without the severe side effects of current therapies
Solution Approach 2:
The patent uses HIF-1α and HIF-2α stabilization as an intermediary mechanism to restore immune system function. These stabilized factors act as mediators that coordinate the immune response, promoting resolution of inflammation and tissue repair while avoiding the direct immunosuppression that causes harmful side effects in current treatments
2Reliability
If surgical intervention is performed to remove parts of the colon, then the immediate threat to life is addressed, but the complexity of the treatment increases and long-term quality of life is affected
Solution Approach 1:
The patent applies preliminary action by stabilizing HIF-1α and HIF-2α to prevent progression to severe colitis requiring surgery. The compounds are administered early in the disease course to restore immune function and prevent tissue damage, avoiding the need for surgical intervention and its associated complexity and long-term complications
Data Source
Figure 1
Figure 2a~2c
Figure 3
AI summary
Disclosed herein are compositions and methods for treating colitis and other inflammatory bowel diseases, inter alia, indeterminate colitis, Crohn's disease, irritable bowel syndrome and ischemic colitis.